BRCA2 and metastatic neoplasm: When comparing baseline characteristics between our series of patients who harbored germline BRCA1 mutant tumors versus those with BRCA2 mutant cancers, both groups were well balanced for baseline characteristics, including tumor type, platinum sensitivity, baseline sites of metastatic disease, and number of prior lines of chemotherapy (Supplementary Tables 3 and 4).